Abstract：Objective To investigate the effect of gefitinib in the treatment of stage IV non-small cell lung cancer (NSCLC). Methods A total of 72 patients with stage IV NSCLC in our hospital were divided into the observation group (n=34) and the control group (n=38). Patients in the control group were treated with cisplatin plus pimitrex, while patients in the observation group were given cisplatin plus gefitinib. The therapeutic effects and tumor marker changes in the two groups were compared. Results The short-term curative effect of the observation group was significantly better than that of the control group (P<0.05), which of clinical effective rates were 91.18% and 81.58%, respectively; The rates of bone marrow suppression and diarrhea in the observation group were significantly higher than those in the control group (P<0.05);After treatment, the paracancerous antigen (CEA), cytokeratin fragment 21-1 (CYFRA21-1) and squamous cell carcinoma antigen (SCCA) in the observation group were (30.03±11.02) g/L, (25.58±6.22)g/L and (25.50±5.44) g/L,respectively, which were significantly lower than those of the control group (P<0.05).The median progression-free survival time and overall survival in the observation group were 9 months and 13 months, respectively, which were significantly longer than those in the control group (5 months and 9 months, respectively) (P<0.05). Conclusion Gefitinib has good clinical efficacy in the treatment of stage Ⅳ non-small cell lung cancer patients, which can significantly reduce CEA, CYFRA21-1 and SCCA levels. It is worthy of clinical use.
潘鑫焱, 李志民. 吉非替尼治疗Ⅳ期非小细胞肺癌的效果及对肿瘤标志物水平的影响[J]. 医学临床研究, 2019, 36(2): 274-287.
PAN Xin-yan, LI Zhi-min. Effect of Gefitinib on Tumor Markers of Stage IV Non-small Cell Lung Cancer Chemotherapy. JOURNAL OF CLINICAL RESEARCH, 2019, 36(2): 274-287.
2019, Vol. 36 
